UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies
NCT ID: NCT00578045
Last Updated: 2015-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1
INTERVENTIONAL
2006-07-31
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase II Study of Umbilical Cord Blood Transplantation
NCT00676806
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies
NCT00514722
Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells
NCT01092026
Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies
NCT00513318
Cord Blood Stem Cell Transplantation Study (COBLT)
NCT00000603
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
Transfusion
Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transfusion
Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Karnofsky performance score \> 60, unless due to disease and then \> 50.
* Age \> 18 years.
* An expected survival of \> 3 months.
* Subjects must have signed an IRB-approved consent and been informed about the investigational nature of the study.
* Cord blood must have negative serology for HIV.
* Release of cord blood.
* The nucleated cell count of the CBU shall equal or exceed 1 x 107 per kg of recipient body weight.
Exclusion Criteria
* Creatinine \> 3.0 mg/dL.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Arkansas
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Arkansas for Medical Sciences
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frits van Rhee, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Arkansas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
67363
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.